Running summarizing tools on a new article

Check the paper below, then start its synthesis.


The microbiome in cancer

Anqi Lin (Zhujiang Hospital, Kangda College of Nanjing Medical University), Minying Xiong (Zhujiang Hospital, Southern Medical University), Aimin Jiang (Second Military Medical University, Changhai Hospital), Li‐Hua Huang (Zhujiang Hospital, Southern Medical University), Hank Z. H. Wong (University of Hong Kong), Suyin Feng (Kangda College of Nanjing Medical University), Chunyan Zhang (Zhujiang Hospital, Southern Medical University), Haijun Yu (Zhujiang Hospital, Southern Medical University), Li Chen (University of Macau), Hao Chi (Southwest Medical University), Pengpeng Zhang (Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University), Bicheng Ye (Zhongda Hospital Southeast University, Southeast University), Hengguo Zhang (Anhui Medical University), Nan Zhang (Huazhong University of Science and Technology), Lingxuan Zhu (Zhujiang Hospital, Southern Medical University), Weiming Mou (Zhujiang Hospital, Southern Medical University), Junyi Shen (Zhujiang Hospital, Southern Medical University), Kailai Li (Zhujiang Hospital, Southern Medical University), Wentao Xu (Zhujiang Hospital, Southern Medical University), Haoxuan Ying (Zhujiang Hospital, Southern Medical University), Cangang Zhang (Zhujiang Hospital, Southern Medical University), Dongqiang Zeng (Nanfang Hospital, Southern Medical University), Jindong Xie (Sun Yat-sen University, Sun Yat-sen University Cancer Center), Xinpei Deng (Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China), Qi Wang (Shanghai Jiao Tong University, Ruijin Hospital), Jianying Xu (LMU Klinikum, University of Glasgow), Wenjie Shi (University Hospital Magdeburg, Otto-von-Guericke-Universität Magdeburg), Chang Qi (TU Wien), Chunrun Qu (University of Oxford, Ludwig Cancer Research), Xufeng Huang (University of Debrecen), András Hajdú (University of Debrecen), Chaoqun Li (UPMC Hillman Cancer Center, University of Pittsburgh Medical Center), Changmin Peng (George Washington University), Xuanye Cao (Baylor College of Medicine), Guangsheng Pei (The University of Texas Health Science Center at Houston), Lin Zhang (Monash University), Yujia Huo (Monash University), Jiabao Xu (LMU Klinikum, University of Glasgow), Antonino Glaviano (University of Palermo), Attila Gábor Szöllősi (University of Debrecen), Sicheng Bian (MetroHealth, Case Western Reserve University), Zhengrui Li (Shanghai Jiao Tong University, Shanghai Ninth People's Hospital), Hailin Tang (Sun Yat-sen University, Sun Yat-sen University Cancer Center), Bufu Tang (Fudan University, Zhongshan Hospital), Zaoqu Liu (Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Jian Zhang (Zhujiang Hospital, Southern Medical University), Kai Miao (University of Macau), Quan Cheng (Central South University, Xiangya Hospital Central South University), Ting Wei (Zhujiang Hospital, Southern Medical University), Shuofeng Yuan (University of Hong Kong - Shenzhen Hospital, University of Hong Kong), Peng Luo (Zhujiang Hospital, Kangda College of Nanjing Medical University)

iMeta
DOI: 10.1002/imt2.70070 (Biochemistry, Genetics and Molecular Biology)
License: CC BY

Abstract: The human microbiome is now recognized as a central regulator of cancer biology, intricately shaping tumor development, immune dynamics, and therapeutic response. This comprehensive review delineates the multifaceted roles of bacteria, viruses, and fungi in modulating the tumor microenvironment and systemic immunity across diverse cancer types. We synthesize current evidence on how microbial dysbiosis promotes carcinogenesis via chronic inflammation, metabolic reprogramming, genotoxic stress, immune evasion, and epigenetic remodeling. This review emphasizes organ-specific microbiome signatures and highlights their potential as non-invasive biomarkers for early detection, treatment stratification, and prognosis. Furthermore, we explore the impact of intratumoral microbiota on cancer therapies, uncovering how microbial metabolites and host-microbe interactions shape therapeutic efficacy and resistance. Finally, advances in microbiome-targeted strategies, such as probiotics, fecal microbiota transplantation, and engineered microbes offer new avenues for adjunctive cancer therapy. This review provides a roadmap for future investigation and underscores the transformative promise of microbiome modulation in cancer prevention and treatment.

Published on 30 Aug. 2025